August Troendle Sells 458 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 458 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $600.39, for a total transaction of $274,978.62. Following the completion of the sale, the chief executive officer owned 603,978 shares of the company’s stock, valued at $362,622,351.42. The trade was a 0.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Medpace Price Performance

NASDAQ:MEDP traded down $3.45 during midday trading on Friday, reaching $578.50. The stock had a trading volume of 215,633 shares, compared to its average volume of 352,984. The stock has a market capitalization of $16.15 billion, a P/E ratio of 33.91, a PEG ratio of 2.66 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The firm’s fifty day simple moving average is $533.75 and its 200-day simple moving average is $491.74.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. BOKF NA boosted its stake in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after buying an additional 20 shares in the last quarter. Valeo Financial Advisors LLC lifted its holdings in shares of Medpace by 5.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after acquiring an additional 21 shares during the period. UMB Bank n.a. boosted its position in shares of Medpace by 5.6% during the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after acquiring an additional 24 shares in the last quarter. Schulhoff & Co. Inc. increased its stake in Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after acquiring an additional 25 shares during the period. Finally, Balefire LLC increased its stake in Medpace by 6.1% in the first quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after acquiring an additional 26 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MEDP. BMO Capital Markets upped their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. TD Cowen boosted their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Finally, Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and upped their price objective for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.